About Transenterix (NYSE:TRXC)
TransEnterix, Inc. is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company's ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. The SurgiBot System is designed as a single-incision, patient-side robotic-assisted surgery system. The Company also develops and manufactures laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: N/A
- Symbol: NYSE:TRXC
- CUSIP: N/A
- Web: www.transenterix.com
- Market Cap: $515.42 million
- Outstanding Shares: 148,536,000
- 50 Day Moving Avg: $1.63
- 200 Day Moving Avg: $0.95
- 52 Week Range: $0.45 - $5.00
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.38
- P/E Growth: 0.00
- Annual Revenue: $5.05 million
- Price / Sales: 102.06
- Book Value: $0.83 per share
- Price / Book: 4.18
- EBITDA: ($47,820,000.00)
- Net Margins: -928.85%
- Return on Equity: -49.16%
- Return on Assets: -33.51%
- Average Volume: 6.03 million shs.
- Short Ratio: 5.58
Frequently Asked Questions for Transenterix (NYSE:TRXC)
What is Transenterix's stock symbol?
Transenterix trades on the New York Stock Exchange (NYSE) under the ticker symbol "TRXC."
How were Transenterix's earnings last quarter?
Transenterix Inc (NYSE:TRXC) posted its earnings results on Monday, March, 6th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. Transenterix had a negative return on equity of 49.16% and a negative net margin of 928.85%. View Transenterix's Earnings History.
Where is Transenterix's stock going? Where will Transenterix's stock price be in 2017?
1 brokerages have issued 12-month price objectives for Transenterix's stock. Their forecasts range from $2.75 to $2.75. On average, they expect Transenterix's stock price to reach $2.75 in the next year. View Analyst Ratings for Transenterix.
Are investors shorting Transenterix?
Transenterix saw a drop in short interest during the month of September. As of September 29th, there was short interest totalling 7,724,447 shares, a drop of 9.6% from the September 15th total of 8,540,542 shares. Based on an average trading volume of 1,694,087 shares, the short-interest ratio is currently 4.6 days. Approximately 8.0% of the shares of the company are sold short.
Who are some of Transenterix's key competitors?
Some companies that are related to Transenterix include Orthofix International N.V. (OFIX), Intersect ENT (XENT), Cardiovascular Systems (CSII), K2M Group Holdings (KTWO), AtriCure (ATRC), CryoLife (CRY), Meridian Bioscience (VIVO), Landauer (LDR), Consort Medical plc (CSRT), STAAR Surgical Company (STAA), Invacare Corporation (IVC), Exactech (EXAC), Antares Pharma (ATRS), Sientra (SIEN), Utah Medical Products (UTMD), Ocular Therapeutix (OCUL), T2 Biosystems (TTOO) and SeaSpine Holdings Corporation (SPNE).
Who are Transenterix's key executives?
Transenterix's management team includes the folowing people:
- Paul A. LaViolette, Independent Chairman of the Board
- Todd M. Pope, President, Chief Executive Officer, Director
- Joseph P. Slattery CPA, Chief Financial Officer, Executive Vice President, IR Contact Officer
- Anthony Fernando, Chief Operating Officer
- Andrea Biffi, Director
- Dennis J. Dougherty, Independent Director
- Jane H. Hsiao Ph.D., Independent Director
- William N. Kelley M.D., Independent Director
- Aftab R. Kherani M.D., Independent Director
How do I buy Transenterix stock?
Shares of Transenterix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Transenterix's stock price today?
MarketBeat Community Rating for Transenterix (NYSE TRXC)MarketBeat's community ratings are surveys of what our community members think about Transenterix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Transenterix stock can currently be purchased for approximately $3.47.
Consensus Ratings for Transenterix (NYSE:TRXC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$2.75 (20.75% downside)|Consensus Price Target History for Transenterix (NYSE:TRXC)
Analysts' Ratings History for Transenterix (NYSE:TRXC)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|3/12/2017||B. Riley||Reiterated Rating||Buy||$2.75||Medium|
|1/19/2017||Raymond James Financial, Inc.||Downgrade||Outperform -> Mkt Perform||N/A|
|5/16/2016||Sterne Agee CRT||Reiterated Rating||Buy||N/A|
|5/11/2016||Lake Street Capital||Downgrade||Buy -> Hold||$2.00||N/A|
|4/18/2016||BTIG Research||Downgrade||Buy -> Neutral||$6.00||N/A|
Earnings History for Transenterix (NYSE:TRXC)Earnings History by Quarter for Transenterix (NYSE TRXC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2016||Q316||($0.10)||($0.11)||$1.80 million||$1.50 million||View||Listen|
|2/24/2015||Q414||($0.18)||($0.13)||$50.00 million||$0.13 million||View||N/A|
|11/6/2014||Q3||($0.18)||($0.18)||$0.10 million||$0.06 million||View||N/A|
Earnings Estimates for Transenterix (NYSE:TRXC)
Current Year EPS Consensus Estimate: $-0.40 EPS
Next Year EPS Consensus Estimate: $-0.37 EPS
Dividend History for Transenterix (NYSE:TRXC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Transenterix (NYSE:TRXC)Insider Trades by Quarter for Transenterix (NYSE:TRXC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/4/2017||S.P.A Sofar||Major Shareholder||Buy||3,722,685||$1.40||$5,211,759.00|| |
|8/22/2016||Andrea Biffi||Director||Buy||40,000||$1.40||$56,000.00|| |
|6/14/2016||Anthony C J Fernando||CTO||Buy||27,000||$1.46||$39,420.00|| |
|5/13/2016||Joseph P Slattery||CFO||Buy||50,000||$1.92||$96,000.00|| |
|11/16/2015||Andrea Biffi||Director||Buy||25,000||$2.81||$70,250.00|| |
|11/13/2015||Willam N Kelley||Director||Buy||20,000||$2.80||$56,000.00|| |
|11/12/2015||Joseph P Slattery||CFO||Buy||15,000||$2.77||$41,550.00|| |
|10/2/2014||Joseph P Slattery||CFO||Sell||33,000||$4.19||$138,270.00|| |
|9/8/2014||Richard Mueller||COO||Sell||3,000||$3.60||$10,800.00|| |
|9/8/2014||Todd Pope||CEO||Sell||50,000||$3.70||$185,000.00|| |
|4/21/2014||Aisling Capital Iii Lp||Major Shareholder||Buy||1,037,767||$4.00||$4,151,068.00|| |
|4/21/2014||William N Starling Jr||Director||Buy||221,450||$4.00||$885,800.00|| |
Headline Trends for Transenterix (NYSE:TRXC)
Latest Headlines for Transenterix (NYSE:TRXC)
Loading headlines, please wait.
Transenterix (TRXC) Chart for Monday, October, 23, 2017